Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.
about
Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptorRole of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.Role of Receptor Tyrosine Kinase Signaling in Renal FibrosisHuman conditions of insulin-like growth factor-I (IGF-I) deficiencyRegulation of IGFBP-1 in Metabolic DiseasesSize of the Ovulatory Follicle Dictates Spatial Differences in the Oviductal Transcriptome in CattleDesign of an Insulin Analog with Enhanced Receptor Binding Selectivity: RATIONALE, STRUCTURE, AND THERAPEUTIC IMPLICATIONSThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialCross-talk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditionsDevelopment of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkersThe insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endotheliumExogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.Insulin-like growth factor binding proteins: a structural perspective.A Linear Mixed Model Spline Framework for Analysing Time Course 'Omics' DataInhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding.Hepatocyte expression of serum response factor is essential for liver function, hepatocyte proliferation and survival, and postnatal body growth in miceNovel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancerThe endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathyHypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways.Mapping a new spontaneous preterm birth susceptibility gene, IGF1R, using linkage, haplotype sharing, and association analysis.Insulin-like growth factor 1-mediated hyperthermia involves anterior hypothalamic insulin receptors.AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Novel function of pregnancy-associated plasma protein A: promotes endometrium receptivity by up-regulating N-fucosylationIGF1 Shapes Macrophage Activation in Response to Immunometabolic Challenge.Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion developmentCirculating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-i-stimulated AKT activation and vascular smooth muscle cell survival.Feed allowance and maternal backfat levels during gestation influence maternal cortisol levels, milk fat composition and offspring growth.Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function.The proliferating role of insulin and insulin-like growth factors in cancer.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging.Lung cancer therapeutics that target signaling pathways: an update.PEAK1, a novel kinase target in the fight against cancer.Differential Effects of Insulin-Like Growth Factor Binding Protein-6 (IGFBP-6) on Migration of Two Ovarian Cancer Cell LinesGli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines.Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation.Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes.
P2860
Q24306866-EAE0DFBE-7A69-4312-B71E-534DE2D0DC72Q24645123-0491D56B-EEA9-4AD1-8BFE-42672738C50CQ26743407-9FA7A7CB-BE90-441E-A69F-B5AB5991131FQ26822806-140C513F-7263-4F97-8C23-65761C540A13Q26863680-BFDBFE98-3907-497F-8B34-E1A49ACEF1B5Q27334391-6096C121-3076-44F7-BC8D-AB510BAC77FBQ27657527-E973C7E1-3D63-4790-9A15-84E9C198CF33Q28075927-9C935889-1F72-4D5C-A82E-76089171657EQ28114971-BCF6F289-377E-4205-BAAA-EB34F5EB7159Q28484376-339FB672-3034-4C33-A5E7-78C6B7B6F191Q28508627-0681B46C-2749-4AA7-BB58-D74BADCB8AE3Q30384833-AA1DAB87-8191-47C0-8534-D31BE6000ED3Q30417447-845340AE-0B81-47EB-9A4B-F5558B622A5AQ30990318-E48BD99A-9CB0-4FEA-BB36-DDB738B3356DQ33330587-E5B8CD68-B1A7-4697-A2BE-B5745C4BEF30Q33606382-B809EDB1-C0DE-41D7-B992-8637C2C6A2F5Q33698278-EECD7059-81D0-4CF4-A9FB-4561B59983D7Q33717397-9CD2489B-ECE4-4B21-B6D0-A6F13BD6689EQ33778092-75CD87D0-BA86-441C-957B-7FBFE38FE0F4Q33778367-345ABAC2-D2F6-48B9-A184-646A96C11D59Q33815411-BE51C444-9687-487A-BAFF-6954FA6A0F7BQ33823428-CF570D05-07F2-44CF-9B19-0A4727FA0DFBQ33874358-2A02A727-4D04-47C4-95D7-E86902A7F2BEQ33890792-AC78FBC2-BB82-47AB-B2A7-F1DE0E2FCA15Q33902764-1D4E4A5C-C730-4FE1-8AD6-B76CE2E1D5BCQ33910916-83E9350C-3659-4A01-9D1B-6B8097CC9C5EQ34092815-234471E5-C0BC-4922-B16A-D68A54687CDDQ34099919-F51C9B04-2D95-4AD4-BFC5-F9D3F57B8566Q34121608-D0018606-851D-4510-AC39-62C161FC34BBQ34127008-75A08C71-2427-4E4D-A466-AF09D40C0EF1Q34136335-5B1C821D-7D2F-4FF4-9E0D-19874A0B5CBCQ34172625-800E6C62-EF9E-4AB6-8DAB-0AD41A86D17FQ34336988-BD1E4A1B-035F-43E6-B2CC-168C616D896CQ34349858-F181FCFD-4E87-46FF-B87F-1D5A86B2D151Q34541960-65A55882-5923-4BAD-B141-F2074037D353Q34675121-A5846EC9-07FA-4EA3-8DCB-F8E51932ECCCQ34818399-80264853-2BDA-4662-86E2-6D2EE18A69A6Q34836999-F80D7546-BD2D-4B44-ADE2-123D801B288DQ34993028-7D4C0064-D45F-4034-9F0B-7B6D5D98658EQ35146163-7C9717A4-6B58-46F2-A1A9-8F9B5225C28E
P2860
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Modifying IGF1 activity: an ap ...... s, atherosclerosis and cancer.
@en
type
label
Modifying IGF1 activity: an ap ...... s, atherosclerosis and cancer.
@en
prefLabel
Modifying IGF1 activity: an ap ...... s, atherosclerosis and cancer.
@en
P2860
P356
P1476
Modifying IGF1 activity: an ap ...... s, atherosclerosis and cancer.
@en
P2093
David R Clemmons
P2860
P2888
P304
P356
10.1038/NRD2359
P577
2007-10-01T00:00:00Z
P5875
P6179
1035189756